Is The Temperature Right for Investing in ASX Healthcare Stocks?

Team Veye | 23-May-2024

The healthcare industry comprises of different sub industries, each subdivision having different dynamics. Investing in Healthcare Market needs deep insight into the underlying drivers.

The Australian healthcare sector is performing well and growing at a fast pace. Advancements in gene therapies and immunotherapies are significantly enhancing quality of life. Clinical trials for new treatments are indicative of future growth potential of many ASX Healthcare Companies.

The potential to generate new revenue and profits for innovative companies that deliver these products is enormous. Once developed, healthcare shares offer twin advantage of stability and growth potential.

The global population continues to grow and age, thus enhancing demand for healthcare services and Best Healthcare Stocks is likely to remain robust, presenting investors with compelling opportunities.

Top ASX Healthcare Stocks are :- 

Mesoblast Limited (ASX: MSB) 

Mesoblast Limited recently received notification from the United States Food and Drug Administration (FDA) subsequent to its Type C meeting. The FDA, after further evaluation of the available clinical data from its Phase 3 study MSB-GVHD001, determined it to be adequate to support the submission of the proposed Biologics License Application (BLA) for remestemcel-L. This application is intended for the treatment of pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD).

In the short term, the company will maintain its focus on advancing key regulatory activities throughout its clinical pipeline. Particularly noteworthy is the plan to submit a resubmission of the Biologics License Application (BLA), potentially leading to approval for Ryoncil by the second half of 2024. Additionally, the company intends to continue advancing trial work, with the second Phase 3 trial for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) currently underway.

The company's pipeline and portfolio of clinical developments remain highly promising, particularly given the significant market opportunities associated with each treatment candidate. With substantial progress in regulatory activities and key approvals underway, the company is poised to significantly enhance its market positioning efforts in 2024. 

Argenica Therapeutics Limited (ASX: AGN)

Argenica Therapeutics Limited recently unveiled promising results from a pilot study assessing the efficacy of their novel drug, ARG-007, in treating mild to moderate traumatic brain injury (TBI) using a ferret model. This study marks a significant advancement in mirroring human brain structure, offering insights into ARG-007's therapeutic potential.

The study revealed compelling evidence of ARG-007's efficacy across multiple fronts. Arqenica is focused on advancing ARG-007's development, especially for treating acute ischaemic stroke. They are also looking into using it for other brain conditions like traumatic brain injury and Alzheimer's disease. As they continue clinical trials and research, ARG-007 shows promise in helping people with serious neurological problems, which could lead to better treatments and outcomes for patients.

Cynata Therapeutics Limited (ASX: CYP)

Cynata Therapeutics Limited specializes in clinical-stage stem cell and regenerative medicine. The company's primary focus lies in advancing therapies built on Cymerus, a cutting-edge therapeutic stem cell platform.

The company is poised to sustain its strong momentum of progress across its clinical pipeline, with several key trials currently underway. A primary focus for the fiscal year 2024 entails completing patient enrolment for the Phase 2 clinical trial for aGvHD. Presently, this enrolment is at 5% completion, with full enrolment anticipated by the conclusion of 2024. The release of results is expected in the second half of 2025, marking significant milestones for the company in the medium term. Concurrently, progress continues on other clinical trials, such as the Phase 1 clinical trial for DFU, which is nearing completion, with the last patient visit scheduled for September 2024. Final results for this trial are anticipated by late 2024 or early 2025. 

Cynata's primary investment appeal stems from its advanced clinical position, which exposes it to a highly lucrative market opportunity of significant scale. This positioning provides the company with a robust foundation for sales. Particularly noteworthy is the company's advancement in clinical trials targeting Osteoarthritis (OA), which represents one of the most promising market opportunities, estimated at over US$10 billion.


Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website, and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.

veye logo

Grab Your Free Report On 5 ASX Dividend Stocks To Buy In 2024